The Buprenorphine/Naloxone combination product, referred to here as Бупраксон, is a commonly used medication in the comprehensive treatment of Opioid Use Disorder (OUD). It is a foundational component of medication-assisted treatment (MAT). The medication is used for managing opioid dependence and is considered relevant support for both stabilization and long-term recovery.

The primary indications include OUD, chronic opioid dependence, and the management of withdrawal symptoms and persistent drug cravings. This medication is generally applied when supportive symptom management is appropriate for patients seeking long-term stability.

“This approach may assist with providing patients the opportunity to focus on other treatment aspects by easing the immediate burden of physical dependence.”

By assisting with functional stability, the medication helps patients cope more steadily with symptom fluctuations, enabling them to remain engaged in counseling and potentially improve their overall quality of life.

Quick Fact: Relief for Opioid Use Disorder
Primary Domain: Long-term management of chronic opioid dependence.
Key Symptom Relief: Management of physical withdrawal symptoms and lessening of compulsive cravings.
Core Benefit: Contributes to maintaining functional stability and supports patient engagement during recovery treatment.

Regulatory References

1. NIH MedlinePlus overview

Eligibility and Contraindications

Бупраксон is a prescription medicine whose eligibility is strictly defined by regulatory health authorities to mitigate specific, serious risks, particularly seizures.

Absolute Prohibitions (Contraindications)

The medicine must not be used by individuals who have a:

• Seizure disorder or a history of seizures.
• Current or prior diagnosis of bulimia nervosa or anorexia nervosa.
• Need to discontinue abruptly the use of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.
• Concurrent use of Monoamine Oxidase Inhibitors (MAOIs), including linezolid or intravenous methylene blue; a 14-day washout period is mandatory after stopping an MAOI before starting this medicine.
• Concurrent use of any other medicine that contains bupropion, to avoid dose-related seizure risk.
• Angle-closure glaucoma.

---

Restrictions and Specific Populations

Population Group	Eligibility Status (Regulatory Basis)
Pediatric Patients (<18 years)	Use Not Approved: Safety and effectiveness have not been established.
Hepatic Impairment (Severe)	Restricted Use: Requires a significant dose reduction and/or less frequent dosing.
Renal Impairment	Restricted Use: Requires consideration for reduced dose and/or frequency.
Pregnancy/Lactation	Requires individual risk-benefit assessment; the drug and its metabolites pass into breast milk.

Interactions with other medicines and products

Official regulatory information for Бупраксон (Buprenorphine/Naloxone) defines specific interaction risks based on pharmacodynamic effects and metabolic pathways.

Interaction Classifications

Classification	Official Regulatory Information
Contraindicated Combination	Co-administration with Naltrexone is strictly prohibited due to the confirmed risk of precipitating acute opioid withdrawal.
Serious Pharmacodynamic Risk	Concomitant use with CNS Depressants (including benzodiazepines, other opioids, and Alcohol) has a documented additive effect that increases the risk of profound sedation and respiratory depression.
Metabolic Modification Risk	The drug is metabolized by the CYP3A4 enzyme. Co-administration with CYP3A4 inhibitors (e.g., specific antiretrovirals) may increase Buprenorphine plasma concentration, while CYP3A4 inducers (e.g., Rifampicin, St. John’s Wort) may decrease it.

Restrictions and Conditions

Timing-Based Condition: The label requires that administration must be delayed until the patient exhibits objective signs of moderate opioid withdrawal when transitioning from full opioid agonists to prevent precipitated withdrawal. Population-Specific Note: Use is not recommended in the presence of Severe Hepatic Impairment due to reduced drug clearance leading to increased systemic exposure. Concomitant use with Serotonergic Drugs carries a risk of serotonin syndrome.

How Бупраксон Works

This section explains the drug's action at the biological level, outlining its targets and the resulting physiological changes.

---

Dual-Mechanism Receptor Modulation (Partial Agonism)

The drug's primary action involves specific binding to the mu (mu) opioid receptor (MOR) where it acts as a partial agonist. This means it only produces a limited, submaximal activation of the receptor, regardless of the drug concentration. This sustained, partial activation modulates the activity of nociceptive signaling pathways.

---

Multi-Target Opioid System Interaction

Beyond the mu-receptor, the drug exhibits a mixed mechanistic profile by simultaneously interacting with other opioid receptor subtypes. It acts as an antagonist (blocker) at the kappa (kappa) receptor (KOR) and a weak agonist at the delta (delta) receptor (DOR). This interaction with multiple receptors results in a complex modulation of the broader opioid system, which shapes its distinct physiological effect profile.

---

⏳ High-Affinity, Prolonged Receptor Occupancy

The drug binds to the mu-opioid receptor with high affinity and remains attached for a prolonged duration. This sustained occupancy not only ensures a long-lasting modulatory effect but also functionally blocks full agonists from accessing the receptor site. This mechanism influences the regulatory feedback of the pathway and limits the degree of mu-opioid system activation, thereby defining the sustained nature of its physiological effects.

How Бупраксон is Used

The Buprenorphine/Naloxone fixed-dose combination product (Бупраксон) is administered as part of a structured approach for the maintenance treatment of Opioid Use Disorder (OUD). The administration route is transmucosal, meaning the dosage unit—either a sublingual tablet or film—must be placed under the tongue (sublingual) or against the inside of the cheek (buccal) until it is completely dissolved. It is required that the product not be cut, chewed, or swallowed, and patients are typically instructed to avoid eating or drinking while the medication is dissolving.

Dosing and Schedule

Usage involves a progression through two distinct phases:

• Induction: Treatment initiation, typically on Day 1, occurs only when objective signs of moderate opioid withdrawal are present, usually 6 hours or more after the last use of a short-acting opioid. The total dose on Day 1 is administered in divided doses, generally up to 8 mg/2 mg (Buprenorphine/Naloxone).
• Maintenance: Following induction, the dose is adjusted to meet patient needs, most commonly stabilizing at 16 mg/4 mg as a single daily dose. The maximum daily dose is 24 mg/6 mg.

Specific Use Constraints

Specific parameters apply to certain populations. For instance, patients with mild-to-moderate hepatic impairment require lower initial doses and careful titration, while the use of this combination is generally avoided in severe hepatic impairment. The adult dosing regimen applies to adolescents aged 15 and older. Discontinuation of treatment, when warranted, involves a gradual tapering of the dose to minimize physiological effects.

Research Evidence / Overview of Studies for Бупраксон (Buprenorphine/Naloxone)

---

Evidence for Use in Opioid Use Disorder (OUD) Maintenance

Research examining the use of this medication for stabilization and maintenance treatment of Opioid Use Disorder (OUD) includes various study types. The evidence was evaluated in Randomized Controlled Trials (RCTs)—which often focused on short-term outcomes—and large-scale observational studies that monitored patients over longer periods in real-world settings. Key study outcomes examined include how long individuals stayed engaged in treatment (treatment retention) and the status of illicit opioid use reported during the study period. Research primarily focused on the outcomes related to the Buprenorphine component.

Evidence for Use in Managing Opioid Withdrawal Symptoms

Research supporting the use of this medication during the initial phase of treatment was evaluated in short-term Randomized Controlled Trials (RCTs). The main focus of these trials was on outcomes related to physical discomfort and the severity of opioid withdrawal symptoms, monitored using standardized clinical scales. The available research is strictly limited to the short-term acute phase. Certainty remains low for some of the direct comparison studies that investigated other standard treatments during the withdrawal phase.

---

Long-Term Follow-up and Durability of Study Outcomes

Research was observed in long-term settings by tracking patient populations for periods of one year or more. These studies explored the durability of stability and the long-term patterns related to outcomes such as sustained treatment retention. However, long-term outcomes reflecting daily functioning or activity level outside of the core outcomes of retention and illicit use are not fully characterized by controlled trials.

What Is Still Unknown or Under Study for Бупраксон

Several key areas remain uncertain or are still being studied for the Buprenorphine/Naloxone combination. Data for certain groups remain insufficient, particularly concerning sustained stability and quality of life measures for patients with multiple chronic issues. The main research limitation is that the sample sizes were modest for certain special populations, such as older adults, meaning the results apply only to the populations studied in the trials.

Key Studies & References

1. Buprenorphine/naloxone (Suboxone, Bunavail, and others): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD (Used as MedlinePlus/NIH surrogate for patient-friendly data)
2. Buprenorphine and Naloxone - StatPearls - NCBI Bookshelf - NIH (General medical evidence and pharmacology)
3. Label: BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM - DailyMed - NIH (Regulatory/Dosing/Safety)

Common questions about Бупраксон (FAQ)

Q: Is Бупраксон a prescription medicine, or can it be bought over the counter?

According to official regulatory documents, this medication is available only with a valid prescription from a doctor. It is classified by health authorities as a Schedule III controlled substance due to its composition.

Q: Does Бупраксон affect the ability to drive or operate machinery?

Official prescribing information includes a specific warning that this medication may impair a patient's ability to drive a motor vehicle or operate hazardous machinery. Official information advises caution regarding engaging in these activities until the effects of the medication are known.

Q: Should I take Бупраксон at the same time every day?

Official dosing recommendations generally advise patients to take the medication as a single daily dose. This structure supports a consistent, once-daily dosing schedule as described in the maintenance phase.

Q: What over-the-counter medicines can Бупраксон interact with?

Regulatory information indicates that there are known risks of interaction with entire classes of drugs. These include medications that act as Central Nervous System (CNS) depressants and any other substance that affects the CYP3A4 metabolic pathway in the body.

Q: Can I take Бупраксон if I have had heart problems in the past?

Official drug information reports that this medication may cause certain cardiovascular effects, such as orthostatic hypotension (a drop in blood pressure when standing up). Official documents indicate that caution and monitoring may be necessary for those with cardiovascular concerns.

Q: How long does Бупраксон stay in the body after taking it?

Based on pharmacokinetic studies, the active ingredient Buprenorphine has a prolonged effect. The average half-life is approximately 38 hours, but this can vary widely among individuals, ranging from 25 to 70 hours after it is dissolved under the tongue.

Q: After how many days or weeks does Бупраксон begin to work at full capacity?

Official clinical guidance based on regulatory trials indicates that the maintenance dose, where the drug reaches its stabilizing capacity, is typically achieved within two to four days of starting the initial phase of treatment.

Q: Can Бупраксон cause addiction or dependence?

Official product labeling indicates that the Buprenorphine component is an opioid that can lead to physical dependence, especially with prolonged administration. Due to this potential for physical dependence, the drug is classified as a controlled substance and is subject to monitoring.

Q: What should I do if I notice an unusual reaction after taking Бупраксон?

Regulatory documents state that in cases of unusual reactions, such as signs of a severe allergic response or rapid changes in mood or behavior, the official label states that immediate medical attention and monitoring are necessary.

Q: Is Бупраксон suitable for elderly people over 65?

Official information states that when this drug is used in geriatric patients, the individual should be closely monitored. Monitoring is specifically recommended for signs of sedation and respiratory depression in this population.

Official Storage and Disposal Requirements

Storage Requirements

The medication must be stored safely out of the sight and reach of children and secured in a location inaccessible to others. This requirement is mandatory across regulatory labeling due to the risk of severe, potentially fatal, respiratory depression from accidental pediatric exposure.

Keep the medicine in its original sealed, child-resistant foil pouch until immediately before use to maintain product integrity and stability. Storage conditions should adhere to the specific temperature range listed on the dispensed packaging, generally avoiding excessive heat and moisture.

Disposal Protocol

Due to the risks associated with this controlled substance, unused or expired product must be disposed of according to official regulatory protocols. The preferred method is to utilize a drug take-back program or a mail-back envelope. If these options are not readily available, the FDA directs that the product be removed from its packaging and immediately flushed down the toilet to prevent diversion or accidental ingestion.